127 related articles for article (PubMed ID: 37852628)
21. The assessment of HER2 status in breast cancer: the past, the present, and the future.
Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
[TBL] [Abstract][Full Text] [Related]
22. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.
Pekar G; Kasselaki I; Pekar-Lukacs A; Dekany C; Hellberg D; Tot T
Histopathology; 2019 Jan; 74(2):300-310. PubMed ID: 30113715
[TBL] [Abstract][Full Text] [Related]
23. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
Casterá Redal C; Bernet Vegué L
Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
[TBL] [Abstract][Full Text] [Related]
24. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
25. HER2 status determination using RNA-ISH--a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer.
Alba J; Gutierrez J; Coupe VM; Fernández B; Vázquez-Boquete Á; Alba J; Forteza J; García-Caballero T
Histol Histopathol; 2012 Aug; 27(8):1021-7. PubMed ID: 22763874
[TBL] [Abstract][Full Text] [Related]
26. Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer.
Xu K; Bayani J; Mallon E; Pond GR; Piper T; Hasenburg A; Markopoulos CJ; Dirix L; Seynaeve CM; van de Velde CJH; Rea DW; Bartlett JMS
J Mol Diagn; 2022 Jul; 24(7):775-783. PubMed ID: 35526835
[TBL] [Abstract][Full Text] [Related]
27. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
[TBL] [Abstract][Full Text] [Related]
29. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
30. HER2 immunohistochemical scores provide prognostic information for patients with HER2-type invasive breast cancer.
Tsai YF; Tseng LM; Lien PJ; Hsu CY; Lin YS; King KL; Wang YL; Chao TC; Liu CY; Chiu JH; Yang MH
Histopathology; 2019 Mar; 74(4):578-586. PubMed ID: 30515868
[TBL] [Abstract][Full Text] [Related]
31. Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer.
Tseng YF; Li YC; Lee YH; Hu HW; Zhang MS; Hung TC; Lien HC
Arch Pathol Lab Med; 2024 Mar; 148(3):e48-e56. PubMed ID: 37639453
[TBL] [Abstract][Full Text] [Related]
32. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
33. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
Casterá C; Bernet L
Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
[TBL] [Abstract][Full Text] [Related]
34. HER2-Low Breast Cancers.
Zhang H; Katerji H; Turner BM; Hicks DG
Am J Clin Pathol; 2022 Mar; 157(3):328-336. PubMed ID: 34519765
[TBL] [Abstract][Full Text] [Related]
35. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
[TBL] [Abstract][Full Text] [Related]
37. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
[TBL] [Abstract][Full Text] [Related]
38. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
[TBL] [Abstract][Full Text] [Related]
39. Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0).
Hoda RS; Zarei S; McIntire PJ; Sprague C; Mekhail Y; Carlson DL; Komforti MK; Downs-Kelly EP
Arch Pathol Lab Med; 2022 Jun; 146(6):701-709. PubMed ID: 34559875
[TBL] [Abstract][Full Text] [Related]
40. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]